Penumbra, Inc.

NYSE PEN

Penumbra, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 280.94

Penumbra, Inc. Price to Earnings Ratio (P/E) is 280.94 on January 14, 2025, a 152.41% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Penumbra, Inc. 52-week high Price to Earnings Ratio (P/E) is 569.20 on August 23, 2024, which is 102.60% above the current Price to Earnings Ratio (P/E).
  • Penumbra, Inc. 52-week low Price to Earnings Ratio (P/E) is 70.98 on June 25, 2024, which is -74.73% below the current Price to Earnings Ratio (P/E).
  • Penumbra, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 244.88.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NYSE: PEN

Penumbra, Inc.

CEO Mr. Adam Elsesser J.D.
IPO Date Sept. 18, 2015
Location United States
Headquarters One Penumbra Place
Employees 4,200
Sector Health Care
Industries
Description

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Similar companies

PODD

Insulet Corporation

USD 267.04

-0.35%

INSP

Inspire Medical Systems, Inc.

USD 169.99

-3.10%

TMDX

TransMedics Group, Inc.

USD 62.54

-2.36%

CNMD

CONMED Corporation

USD 67.79

-2.46%

LIVN

LivaNova PLC

USD 47.63

0.66%

INMD

InMode Ltd.

USD 16.07

0.63%

DXCM

DexCom, Inc.

USD 79.17

-0.84%

MASI

Masimo Corporation

USD 166.09

0.31%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

TNDM

Tandem Diabetes Care, Inc.

USD 35.79

-1.16%

NARI

Inari Medical, Inc.

USD 79.30

-0.05%

IRTC

iRhythm Technologies, Inc.

USD 99.01

4.67%

StockViz Staff

January 15, 2025

Any question? Send us an email